Back to Search Start Over

Development of novel lipoplex formulation methodologies to improve large-scale transient transfection for lentiviral vector manufacture.

Authors :
Williams-Fegredo T
Davies L
Knevelman C
Mitrophanous K
Miskin J
Rafiq QA
Source :
Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2024 Apr 26; Vol. 32 (2), pp. 101260. Date of Electronic Publication: 2024 Apr 26 (Print Publication: 2024).
Publication Year :
2024

Abstract

Large-scale transient transfection has advanced significantly over the last 20 years, enabling the effective production of a diverse range of biopharmaceutical products, including viral vectors. However, a number of challenges specifically related to transfection reagent stability and transfection complex preparation times remain. New developments and improved transfection technologies are required to ensure that transient gene expression-based bioprocesses can meet the growing demand for viral vectors. In this paper, we demonstrate that the growth of cationic lipid-based liposomes, an essential step in many cationic lipid-based transfection processes, can be controlled through adoption of low pH (pH 6.40 to pH 6.75) and in low salt concentration (0.2× PBS) formulations, facilitating improved control over the nanoparticle growth kinetics and enhancing particle stability. Such complexes retain the ability to facilitate efficient transfection for prolonged periods compared with standard preparation methodologies. These findings have significant industrial applications for the large-scale manufacture of lentiviral vectors for two principal reasons. First, the alternative preparation strategy enables longer liposome incubation times to be used, facilitating effective control in a good manufacturing practices setting. Second, the improvement in particle stability facilitates the setting of wider process operating ranges, which will significantly improve process robustness and maximise batch-to-batch control and product consistency.<br />Competing Interests: T.W.-F., L.D., C.K., K.M., and J.M. were all employees and stock option holders of Oxford Biomedica (UK) Limited at the time the research was conducted.<br /> (© 2024 The Authors.)

Details

Language :
English
ISSN :
2329-0501
Volume :
32
Issue :
2
Database :
MEDLINE
Journal :
Molecular therapy. Methods & clinical development
Publication Type :
Academic Journal
Accession number :
38745895
Full Text :
https://doi.org/10.1016/j.omtm.2024.101260